The retail turnover (including VAT) of Apranga Group reached EUR 265.8 million in 9 months 2025 and was by 5.7% higher than in corresponding period of 2024. The unaudited consolidated profit before income tax of Apranga Group reached EUR 14.8 million in 9 months 2025, while it amounted to EUR 15.2 million in the same period of 2024. EBITDA of Apranga Group reached EUR 32.1 million in 9 months 2025, while it amounted to EUR 31.2 million in corresponding period of 2024. The unaudited interim consolidated fina ...

Core Points - Trailblazer Acquisition Corp. will allow holders of its initial public offering units to separately trade Class A ordinary shares and warrants starting October 31, 2025 [1] - The separated Class A ordinary shares and warrants will trade on the Nasdaq Global Market under the symbols "BLZR" and "BLZRW," while units that are not separated will continue to trade under the symbol "BLZRU" [1] Company Overview - Trailblazer Acquisition Corp. is a special purpose acquisition company incorporated in the Cayman Islands, aimed at executing mergers, amalgamations, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations with various businesses or entities [2] - The company has the flexibility to pursue initial business combinations across any business or industry [2]

Core Insights - FFW Corporation reported a net income of $1,518,000 or $1.40 per common share for the quarter ended September 30, 2025, an increase from $1,243,000 or $1.09 per common share for the same period in 2024 [2] - The Corporation's net interest income for the quarter was $4,514,000,000, significantly higher than $3,782,000 for the same quarter in 2024 [2] - The return on average common equity improved to 11.90% for the quarter ended September 30, 2025, compared to 9.89% for the same quarter in 2024 [3] Financial Performance - Net income increased to $1,518,000 for Q3 2025 from $1,243,000 in Q3 2024 [2] - Net interest income rose to $4,514,000 from $3,782,000 year-over-year [2] - Total noninterest income slightly decreased to $1,268,000 from $1,280,000 [2] - Noninterest expense increased to $4,002,000 from $3,695,000 [2] Key Ratios - Return on average assets improved to 1.06% in Q3 2025 from 0.86% in Q3 2024 [3] - The equity-to-assets ratio was 9.23% as of September 30, 2025, compared to 8.88% a year earlier [5] - The allowance for credit losses as a percentage of gross loans receivable was 1.34% at September 30, 2025, up from 1.30% at the same time in 2024 [4] Asset and Equity Information - Total assets increased to $572,522,000 as of September 30, 2025, from $570,108,000 at June 30, 2025 [5] - Shareholders' equity rose to $52,856,000 from $49,944,000 during the same period [5] - Nonperforming assets decreased to $7,416,000 from $8,147,000 at June 30, 2025 [4] Share Repurchase Program - The Corporation has an active share repurchase program, having repurchased 729 shares at an average price of $40.00 during the quarter ended September 30, 2025 [5]

After reaching 100 financial service customers, Trust Stamp pushes to expand the use of its privacy-enhancing technologies into the WealthTech SectorAtlanta, GA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Trust Stamp (Nasdaq: IDAI), a global provider of AI-powered Privacy Enhancing Technologies (PETs), announced today that it has joined the Founders Arena, a leading startup accelerator in the WealthTech sector. Trust Stamp President Andrew Gowasack, commented, “While we are proud of reaching 100 financial institutio ...

Core Points - NBCUniversal has renewed its exclusive audio partnership with iHeartMedia for the Milan Cortina 2026 Olympic Winter Games, scheduled from February 6 to February 22, 2026 [1][6] - iHeartRadio will provide 24/7 audio coverage of NBCUniversal's linear programming, including play-by-play channels and original podcasts [1][2] - The partnership aims to enhance audience engagement by delivering Olympic content through various iHeart platforms, including popular podcasts [2][4] NBCUniversal and iHeartMedia Collaboration - The collaboration includes the return of the original iHeartPodcast "Two Guys, Five Rings," hosted by Bowen Yang and Matt Rogers, with weekly episodes launching in early January 2026 [3][4] - iHeartMedia will produce Olympic-themed episodes for its popular podcasts, expanding the reach of Olympic content beyond traditional media [4] Coverage and Content Focus - NBCUniversal's audio coverage will focus on key events such as U.S. team ice hockey, figure skating, speed skating, skiing, and snowboarding, emphasizing Team USA's participation [2][3] - The partnership is expected to deepen the connection between audiences and athletes, showcasing inspiring stories from the Winter Games [3] Historical Context of the Games - The 2026 Olympic Winter Games will take place across multiple venues in northern Italy, marking the second time Cortina has hosted the Olympics and the fourth time Italy has hosted overall [5][6] - NBCUniversal holds the U.S. media rights to the Olympic Games through 2036, covering multiple upcoming Olympic events [7]

Company Overview - High Roller Technologies, Inc. is a leading global online gaming operator known for its innovative casino brands, including High Roller, Fruta, and Kassuuu, listed under the ticker ROLR on the NYSE [3] - The company offers a cutting-edge real-money online casino platform with over 6,000 premium games from more than 90 leading game providers, serving a global customer base [3] - High Roller Technologies emphasizes enhanced search engine optimization, machine learning, seamless direct API integrations, faster load times, and superior scalability in its offerings [3] Upcoming Events - Management will participate in the Spartan Capital Investor Conference 2025 on November 3rd, 2025, at the Marriott Marquis Hotel, New York, NY [1] - CEO Seth Young will deliver a company overview during the presentation, highlighting recent milestones, strategic achievements, and key upcoming developments [2] - One-on-one meetings will be available throughout the conference to discuss the company's growth initiatives and outlook in greater detail [2]

Data from the dose optimization trial expected soonProLectin-M is positioned as the first oral antiviral sugar chemistry drug BOSTON, MASSACHUSETTS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company pioneering innovative therapies for viral diseases, is pleased to announce the successful completion of its second randomized double-blind, placebo-controlled clinical trial for its leading broad-spectrum antiviral drug candidate, ProLectin-M. ...

WUXI, China, Oct. 29, 2025 (GLOBE NEWSWIRE) -- LOBO Technologies Ltd. (NASDAQ: LOBO), a developer and manufacturer of electric mobility and smart energy solutions, today announced that it has received a bulk purchase order valued at approximately US$1.194 million from Terrian Town Limited, a Kenyan real estate company, for its advanced Photovoltaic power storage systems. The systems, which include 10kW photovoltaic arrays paired with 20kWh lithium iron phosphate (LiFePO4) batteries, are designed to support ...

Only one new luxury home remains available for saleCUMMING, Ga., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, announced the final opportunity to purchase a new home at its Brookmeade Trail community, an elegant enclave by Toll Brothers in Cumming, Georgia. The final luxury home in the community is now available for purchase, marking the last chance for home shoppers to purchase a new home in this exceptional neighborhood. Brookmeade Trail is ...

Core Insights - AnaptysBio, Inc. announced positive late-breaking data from a Phase 2b trial of rosnilimab for rheumatoid arthritis, showing durable clinical benefits and a favorable safety profile [1][4][5] Group 1: Trial Overview - The Phase 2b RENOIR trial involved 424 patients with moderate-to-severe rheumatoid arthritis, assessing the efficacy, safety, and tolerability of rosnilimab [3][4] - Patients were either naïve to biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) or had prior treatment experience [3][6] Group 2: Efficacy Results - Positive results were observed at Week 12, with significant efficacy on primary endpoints such as DAS28-CRP and ACR20 across all doses [5] - By Week 28, clinical responses continued to improve, including CDAI remission and ACR50/70 rates, regardless of prior treatments [4][5] - Durable clinical benefits were confirmed for at least three months off drug, with significant reductions in Tph cells by over 90% [4][5] Group 3: Safety Profile - Rosnilimab was well-tolerated throughout the trial, with no treatment-related serious adverse events or malignancies reported [1][4][5] - The trial demonstrated a low dropout rate and no safety trends similar to those seen with JAK inhibitors or other biologics [2][4] Group 4: Mechanism of Action - Rosnilimab targets pathogenic T cells, effectively depleting them while sparing nonpathogenic T cells, which helps maintain overall immune function [8][9] - The drug's mechanism was validated by significant reductions in T cell and B cell activation in synovial biopsies [5]